title: [Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis].
abstract: The issues of steatohepatitis treatment in the pathogenesis of which a major role plays lipid accumulation in hepatocyte and increased processes of free radical oxidation of lipids. Developed a method of treatment of patients with alcoholic and nonalcoholic steatohepatitis with the inclusion of a combination of essential phospholipids (EPL) and silymarin (SM). A comparative assessment of results of treatment with the inclusion of a combination of EPL and SM, Essentiale and Carsil in 60 patients with alcoholic and nonalcoholic steatohepatitis. Revealed the preferential efficiency of combination EPL and SM in these patients in regard of shortening the time clinical manifestations of disease, reducing transaminase activity, normalization of the cholestasis and cholesterol. Given practical recommendations of treatment patients with alcoholic and nonalcoholic steatohepatitis with the inclusion of a combination of EPL and CM.
authors.forename: G N
authors.initials: GN
authors.lastname: Iakimchuk
authors.forename: L N
authors.initials: LN
authors.lastname: Gendrikson
mesh_terms: D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005234:Fatty Liver / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D005235:Fatty Liver, Alcoholic / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000627:therapeutic use*; D012838:Silymarin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010713:Phosphatidylcholines; D012838:Silymarin; C011246:essential 303 forte